Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension of crenezumab after Phase III studies BN29552/BN29553 in Alzheimer's disease
2017-002702-12Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of crenezumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Adverse events. Started May 2018; status: terminated.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-002702-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002702-12.